The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era

Eitemau Tebyg

• The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
  gan: Camille C.B. Kockerols, et al.
  Cyhoeddwyd: (2022-03-01)
• Treatment outcome in a population-based, ‘real-world’ cohort of patients with chronic myeloid leukemia
  gan: Inge G.P. Geelen, et al.
  Cyhoeddwyd: (2017-11-01)
• Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival
  gan: Inge G.P. Geelen, et al.
  Cyhoeddwyd: (2017-12-01)
• Impact of additional cytogenetic aberrations at diagnosis of chronic phase chronic myeloid leukemia
  gan: Fang Cheng, et al.
  Cyhoeddwyd: (2025-09-01)
• Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of MYC Aberrations
  gan: Eva Ondroušková, et al.
  Cyhoeddwyd: (2022-06-01)